INTRODUCTION {#s1}
============

Treatment of mineral metabolism abnormalities is important in managing hemodialysis patients with secondary hyperparathyroidism (SHPT), as a body of evidence suggests that the risk of bone-related and cardiovascular complications is increased under conditions of high serum parathyroid hormone (PTH) levels, hypercalcemia and hyperphosphatemia, possibly via bone remodeling and accelerated vascular calcification \[[@gfw020C1]--[@gfw020C3]\]. To help clinicians recognize abnormalities in mineral metabolism markers, target ranges have been defined for serum PTH, calcium and phosphorus levels in clinical practice guidelines established by the Kidney Disease Outcomes Quality Initiative (KDOQI), Kidney Disease: Improving Global Outcomes (KDIGO) and the Japanese Society for Dialysis Therapy (JSDT) \[[@gfw020C4]--[@gfw020C6]\]. The appropriateness of these target ranges is supported by several studies showing that consistent control of the mineral metabolism makers within their target ranges is associated with improved survival rates among hemodialysis patients \[[@gfw020C7], [@gfw020C8]\]. To achieve these guideline-specified target ranges, each guideline outlines rules regarding the frequency of monitoring mineral metabolism markers (Table [1](#gfw020-T1){ref-type="table"}) \[[@gfw020C4]--[@gfw020C6]\]. However, as noted in the guidelines themselves, evidence supporting these recommended frequencies is admittedly scarce. Table 1Frequency of monitoring for mineral metabolism markers suggested in guidelinesKDOQI 2003 \[4\]JSDT 2008 \[9\] and 2012 \[6\]KDIGO 2009 \[5\]Calcium/phosphorus DefaultMonthlyBiweekly or monthlyEvery 1--3 months Other than defaultMore frequently than default^a^More frequently than default^b^More frequently than default^c^PTH DefaultTrimonthlyTrimonthlyEvery 3--6 months Other than defaultMore frequently than default^a^Monthly^d^More frequently than default^c^[^2][^3][^4][^5][^6]

Findings from a previous study suggested that the PTH target range specified in the KDOQI guidelines was achieved more often after frequency of monitoring mineral markers was switched from quarterly to monthly \[[@gfw020C10]\]. However, given that those results were obtained in a before--after study with no comparison group, conducted at a single center, whether the increased rate of achieving target range PTH levels was due to increased monitoring frequency or due to increased use of cinacalcet or vitamin D receptor activator (VDRA) irrespective of changes in monitoring frequency remains unclear.

Recommended frequencies for monitoring also vary between guidelines, with no firm consensus on optimum frequency (Table [1](#gfw020-T1){ref-type="table"}) \[[@gfw020C4]--[@gfw020C6]\]. In Japan, biweekly or monthly measurement is recommended for calcium/phosphorus \[[@gfw020C6]\], which is more frequent than values defined in the KDOQI or KDIGO guidelines \[[@gfw020C4], [@gfw020C5]\]. Regarding PTH, trimonthly measurement is recommended in Japan \[[@gfw020C6]\], whereas less frequent measurement (every 3--6 months) is recommended in the KDIGO guideline \[[@gfw020C5]\]. Further, our previous study on practice patterns at Japanese dialysis facilities revealed that some facilities have adopted 'intensive monitoring' frequencies, such as weekly measurement for serum calcium/phosphorus levels or monthly measurement for serum PTH levels \[[@gfw020C11]\]. Examination of how real-world variation in measurement frequency for mineral metabolism markers affects adjustments in therapies and likelihood of achievement of target ranges will help clarify the appropriateness of suggestions in existing guidelines.

Here, to examine the extent to which frequency of marker measurement contributes to achievement of target ranges and to therapy adjustment, we analyzed findings from a prospective, large-scale cohort study of hemodialysis patients with SHPT: Mineral and Bone Disorders Outcomes Study for Japanese CKD Stage 5D Patients (MBD-5D).

MATERIALS AND METHODS {#s2}
=====================

The study protocol and waiver of informed consent were approved by the Central Ethics Committee at Kobe University\'s School of Medicine (No. 754).

Target population {#s2a}
-----------------

The target population was chronic kidney disease stage 5D patients with SHPT receiving maintenance hemodialysis. To determine participating facilities, the country was first divided into nine geographical regions, and the number of facilities chosen for each region was made proportional to the number of hemodialysis patients in that region. Facilities were included until the target sample size for the MBD-5D study was reached \[[@gfw020C12]\]. Eligible patients were all who met the following two criteria: (i) those receiving hemodialysis at one of the participating facilities as of 1 January 2008 and (ii) either those with iPTH concentration ≥180 pg/mL or those receiving an intravenous VDRA (calcitriol or maxacalcitol) or an oral active VDRA (falecalcitriol, the only oral VDRA approved in Japan for SHPT treatment). Patients who had been on dialysis for \<3 months were excluded. A total of 3276 patients were registered in the study cohort from among 86 facilities across Japan. Data were collected until January 2011.

Outcomes and exposures {#s2b}
----------------------

We examined four clinical outcomes: achievement or maintenance of guideline-specified ranges of mineral metabolism markers when serum levels were (i) over or (ii) within ranges, respectively, (iii) use of intravenous VDRA and (iv) initiation of cinacalcet use (see conceptual framework in Figure [1](#gfw020-F1){ref-type="fig"}). JSDT-specified target ranges are 3.5--6.0 mg/dL for phosphorus, 8.4--10.0 mg/dL for calcium (albumin-corrected value, see the 'Data collection' section) and 60--180 pg/mL for intact PTH (iPTH) \[[@gfw020C9]\]. Regarding intravenous VDRA, use of calcitriol or maxacalcitol was examined. FIGURE 1Conceptual framework used in regression analyses. MBD markers include serum calcium (Ca), phosphorus (P) and PTH. MBD-related drugs include intravenous VDRAs, phosphate binders and cinacalcet. Guideline (GL) range: target range of MBD markers specified in the JSDT guidelines. Outcome 1 was whether or not future MBD marker levels would achieve their target ranges when their levels were over ranges at previous visit. Outcome 2 was whether or not future MBD marker levels would maintain their target ranges when their levels were within ranges at previous visit. Outcome 3 was whether or not intravenous administration was used in the future. Outcome 4 was whether or not cinacalcet prescription was initiated in the future. BMI, body mass index.

The main exposures were frequencies of measurement for calcium/phosphorus or PTH as a facility policy and were assessed by asking dialysis facility physicians in charge of the MBD-5D study the following: 'In your facility, how often are serum calcium and phosphorus levels usually measured?' with responses of 'weekly', 'biweekly', 'monthly', 'bimonthly', 'when needed' or 'other (with free comments)' and 'In your facility, how often is serum PTH level usually measured?' with responses of 'monthly', 'bimonthly', 'trimonthly', 'every six months', 'when needed' or 'other (with free comments)'.

Responses of 'when needed' were excluded for all three markers, as the true frequency was unknown. Given that no facilities cited a frequency of bimonthly for serum calcium/phosphorus measurement ([Supplementary data, Table S1](#sup1){ref-type="supplementary-material"}), three levels of decreasing frequency were set: weekly/biweekly/monthly (reference, citing KDOQI and JSDT statements) \[[@gfw020C4], [@gfw020C9]\]. With regard to frequency of serum PTH measurement, facilities who reported taking measurements every 4 months or less were excluded, as under our study protocol, data on mineral metabolism markers were collected every 3 months ([Supplementary data, Table S2](#sup1){ref-type="supplementary-material"}). As such, three levels of decreasing frequency were set: monthly/bimonthly/trimonthly (reference, citing KDOQI and JSDT statements) \[[@gfw020C4], [@gfw020C9]\].

Covariates {#s2c}
----------

Covariates used in the analyses included baseline (time of entry into cohort) patient characteristics (age, gender, vintage, primary renal disease, cardiovascular disease, lung disease, liver disease, malignancy and history of parathyroidectomy), levels of mineral and bone disorder (MBD)-related serum markers (calcium, phosphorus and iPTH), prescriptions for MBD-related drugs \[VDRAs (intravenous VDRAs and oral falecalcitriol, calcitriol and alphacalcidol), cinacalcet and phosphate binders\] and other potential confounders (dialysate calcium concentration, Kt/V and serum albumin level).

Data collection {#s2d}
---------------

Data were collected from 86 dialysis facilities by trained staff. Data on demographics and comorbidities were collected at the time of enrollment (Visit 0). Data on MBD markers and treatments were collected at the time of enrollment (Visit 0) and every 3 months for 3 years (Visits 1--12). Data on other time-dependent variables were collected every 6 months, prospectively. The laboratory data used were values measured closest to the end of each visit. Serum iPTH levels (reference: 10--65 pg/mL) were measured at 73 facilities. Serum whole PTH levels obtained using a third-generation PTH assay (immunoradiometric assay; reference: 9--39 pg/mL) were measured at the other 13 facilities and then converted to iPTH levels by multiplying whole PTH values by 1.7, a method that has been validated in a previous study and is recommended in Japanese guidelines \[[@gfw020C9], [@gfw020C13]\]. Serum calcium levels were corrected for albumin concentration using the modified Payne method \[corrected calcium = calcium + (4.0 -- albumin), when albumin levels were \<4.0 g/dL\] \[[@gfw020C14]\], which is recommended in the Japanese dialysis guideline and thus commonly used in Japanese dialysis settings \[[@gfw020C9]\].

Statistical analysis {#s2e}
--------------------

The analytic model for achieving guideline-specified target ranges is shown in [Supplementary data, Table S3](#sup1){ref-type="supplementary-material"}. For each 3-month period ending at Visit *t*, achievement of target range was modeled as a function of treatment-related variables (receipt of VDRAs, phosphate binder or cinacalcet and dialysate calcium concentration) at a given Visit *t* − 1, biochemical variables (calcium, phosphorus, iPTH, Kt/V and serum albumin) at Visit *t* − 2 and baseline data (measurement frequency, age, gender, primary renal disease and vintage). We fitted generalized estimating equations to estimate odds ratios for likelihood of achieving target ranges based on intra-individual repeated measurements, with a separate model fitted for each mineral metabolism marker ([Supplementary data, Table S3](#sup1){ref-type="supplementary-material"}). For analyses when mineral metabolism markers exceeded guideline-specified target ranges, sets were restricted to data with mineral metabolism markers at Visit *t* − 2 above the upper limits of target ranges. For analyses when mineral metabolism markers were within the target ranges, sets were restricted to data with mineral metabolism markers at Visit *t* − 2 within target ranges.

The analytic model for using intravenous VDRA or starting cinacalcet is shown in [Supplementary data, Table S4](#sup1){ref-type="supplementary-material"}. For each 3-month period ending at Visit *t*, use of intravenous VDRA or cinacalcet initiation was modeled as a function of treatment-related variables (receipt of VDRAs, phosphate binder or cinacalcet and dialysate calcium concentration) and biochemical variables (calcium, phosphorus, iPTH, Kt/V and serum albumin) at Visit *t* − 1 and baseline data (measurement frequency, age, gender, primary renal disease and vintage). We fitted generalized estimating equations to estimate odds ratios for likelihood of using intravenous VDRAs or starting cinacalcet, with a separate model fitted for each treatment ([Supplementary data, Table S4](#sup1){ref-type="supplementary-material"}). Analyses on use of intravenous VDRAs used all data sets, whereas sets used for cinacalcet initiation analyses were restricted to those in which cinacalcet prescription at Visit *t* was not initiated or was initiated for the first time at that visit. Sensitivity analyses restricted to facilities using iPTH were also conducted for the analytic models, both for achieving guideline-specified target ranges and for using intravenous VDRA or starting cinacalcet.

Data missing at baseline were replaced by mean or median values or by predicted values from linear regression models. Missing data were imputed by carrying the last observation forward. We used these simple imputation methods because there were markedly few missing values for MBD-related markers of interest (\<0.2% at baseline and ∼2% during follow-up, except for 6% for iPTH).

Statistical significance was set at *P* \< 0.05. SAS 9.4 (SAS Institute, Cary, NC, USA) was used for statistical analyses.

RESULTS {#s3}
=======

Baseline characteristics are shown in Table [2](#gfw020-T2){ref-type="table"}. Across a total of 86 facilities, the mean age was 61.9 years, mean dialysis vintage was 10.1 years, 38.5% of the cases were women, and 44.9 and 24.2% of the cases of primary renal disease were glomerulonephritis and diabetic nephropathy, respectively. Percentages of glomerulonephritis and women in our study population were similar to those of all Japanese dialysis patients in 2007 \[[@gfw020C15]\]. At baseline, the proportions of patients with JSDT-specified target ranges of serum calcium (8.4--10.0 mg/dL), serum phosphorus (3.5--6.0 mg/dL) and serum iPTH (60--180 pg/mL) were 65.4, 63.2 and 14.5%, respectively. The proportions of patients receiving VDRA and phosphate binder at baseline were 77.5 and 85.3%, respectively. Cinacalet was not used, as it was not marketed at baseline. Table 2Study population baseline characteristicsNumber of study sites86Number of patients3276Age \[years, mean (SD)\]61.9 (12.7)Sex (female) (%)38.5Dialysis duration \[years, mean (SD)\]10.1 (8.2)Cause of end-stage renal disease Glomerulonephritis (%)44.9 Diabetic nephropathy (%)24.2 Nephrosclerosis (%)5.8 Polycystic kidney disease (%)4.4 Others/unknown (%)20.8Comorbidities Cardiovascular disease (%)60.0 Lung disease (%)7.3 Liver disease (%)14.0 Malignancy (%)5.0 History of parathyroidectomy (%)6.0Serum albumin \[g/dL, mean (SD)\]3.8 (0.4)Kt/V \[mean (SD)\]1.42 (0.29)Serum calcium^a^ \<8.4 mg/dL (%)9.9 8.4--10.0 mg/dL (%)64.8 \>10.0 mg/dL (%)25.3Serum phosphorus \<3.5 mg/dL (%)4.5 3.5--6.0 mg/dL (%)63.3 \>6.0 mg/dL (%)32.2Serum iPTH \<60 pg/dL (%)2.8 60--180 pg/dL (%)15.0 \>180 pg/dL (%)82.2Dialysate calcium \<3 mg/dL (%)52.0 ≥3 mg/dL (%)48.0VDRA Intravenous (%)48.7 Oral (%)28.8 None (%)22.5Phosphate binder Both (%)23.3 Not calcium-based (%)18.4 Calcium-based (%)43.6 None (%)14.7Cinacalcet^b^ None (%)100[^7][^8][^9]

Regarding frequency of monitoring serum calcium/phosphorus as a facility policy, responses of weekly, biweekly and monthly were given by 4, 69 and 9 facilities, respectively ([Supplementary data, Table S1](#sup1){ref-type="supplementary-material"}). Regarding frequency of monitoring serum PTH, responses of monthly, bimonthly and trimonthly were given by 16, 6 and 33 facilities, respectively ([Supplementary data, Table S2](#sup1){ref-type="supplementary-material"}).

Table [3](#gfw020-T3){ref-type="table"} shows the association of frequency of monitoring and likelihood of achieving guideline-specified target ranges. When serum mineral marker levels exceeded the targeted range, weekly measurement of calcium/phosphorus was positively associated with achieving the guideline-specified calcium range \[adjusted odds ratio (AOR): 1.57, 95% confidence interval (CI) 1.09--2.26\] but not the phosphorus range (AOR: 0.99, 95% CI 0.74--1.33). Monthly measurement of PTH was positively associated with achieving the guideline-specified iPTH range (AOR: 1.14, 95% CI 1.01--1.27). However, when serum marker levels were already within the guideline-specified range, increased frequency of measurements was not associated with in-range maintenance of marker levels for any of the three mineral markers assessed. Table 3Association of monitoring frequency with achievement of guideline-specified ranges for each markerSerum markerMonitoring frequencyPatients with marker levels OVER range at previous visitPatients with marker levels WITHIN range at previous visitSets (*n*)Proportion (%)^a^Relative proportion in-range marker levels \[OR (95% CI)\]^b^Sets (*n*)Proportion (%)^c^Relative proportion in-range marker levels \[OR (95% CI)\]^b^CalciumWeekly28454.91.57 (1.09--2.26)106380.11.11 (0.89--1.38)Biweekly689247.11.10 (0.91--1.32)19 45878.90.96 (0.85--1.09)Monthly107944.9Reference314579.8ReferencePhosphorusWeekly51049.20.99 (0.74--1.33)86170.90.89 (0.72--1.10)Biweekly843247.10.92 (0.78--1.09)18 21373.91.00 (0.90--1.12)Monthly134948.6Reference303774.4ReferencePTHMonthly442929.41.14 (1.01--1.27)299160.90.94 (0.83--1.07)Bimonthly135225.10.96 (0.80--1.16)83758.90.93 (0.76--1.13)Trimonthly856325.5Reference457961.5Reference[^10][^11][^12]

Tables [4](#gfw020-T4){ref-type="table"} and [5](#gfw020-T5){ref-type="table"} show the association of frequency of monitoring and likelihood of therapy adjustment. Increased frequency of measurement of serum calcium/phosphorus was positively associated with cinacalcet initiation (Table [4](#gfw020-T4){ref-type="table"}). For serum PTH, bimonthly---but not monthly---measurement was associated with cinacalcet initiation (AOR: 1.29, 95% CI 1.01--1.64 and AOR: 1.13, 95% CI 0.95--1.35, respectively). Increased frequency of measurement of serum calcium/phosphorus was not associated with intravenous VDRA administration (Table [5](#gfw020-T5){ref-type="table"}). Monthly PTH measurement was associated with intravenous VDRA administration (AOR: 1.54, 95% CI 1.35--1.76). Table 4Association of frequency of monitoring of serum markers with cinacalcet initiationSerum markerMonitoring frequencyInitiation of cinacalcetSets (*n*)Proportion (%)^a^Relative proportion of adjustment \[OR (95% CI)\]^b^Calcium and phosphorusWeekly9237.81.96 (1.35--2.84)Biweekly20 8305.31.26 (1.03--1.55)Monthly34234.4ReferencePTHMonthly60435.11.13 (0.95--1.35)Bimonthly17516.21.29 (1.01--1.64)Trimonthly10 4055.1Reference[^13][^14]Table 5Association of frequency of monitoring of serum markers with adjustment of intravenous VDRA useSerum markerMonitoring frequencyUse of intravenous VDRASets (*n*)Proportion (%)^a^Relative proportion of adjustment \[OR (95% CI)\]^b^Calcium and phosphorusWeekly143055.11.11 (0.87--1.42)Biweekly28 30356.11.14 (0.99--1.30)Monthly459151.8ReferencePTHMonthly807164.11.54 (1.35--1.76)Bimonthly248043.51.02 (0.84--1.24)Trimonthly14 14849.4Reference[^15][^16]

Sensitivity analyses restricted to facilities using iPTH assays yielded similar but slightly stronger associations than those presented in Tables [3](#gfw020-T3){ref-type="table"}--[5](#gfw020-T5){ref-type="table"} ([Supplementary data, Tables S5--S7,](#sup1){ref-type="supplementary-material"} respectively).

DISCUSSION {#s4}
==========

In this prospective cohort study of hemodialysis patients with SHPT, when serum marker levels exceeded the target range, weekly measurement of calcium/phosphorus was positively associated with achieving the guideline-specified calcium range but not the phosphorus range and monthly measurement of PTH was positively associated with achieving the guideline-specified PTH range. However, when serum marker levels were already within the guideline-specified range, increased frequency of measurements was not associated with in-range maintenance of marker levels for any of the three mineral markers assessed. Our results support the notion proposed by clinical practice guidelines that increased frequency of measurements is helpful when serum mineral marker levels exceed the target range, partially via therapy adjustments, but may not be helpful when levels are already within target ranges.

Regarding the appropriate frequency of serum PTH measurements, our present results are consistent with frequencies found in the guidelines of KDOQI 2003 and JSDT. When serum PTH levels exceed the target ranges, KDOQI 2003 and JSDT guidelines recommend more frequent measurements (than trimonthly) \[[@gfw020C4], [@gfw020C6]\]. In the present study, monthly---but not bimonthly---PTH measurement was associated with increased likelihood of achieving target ranges when serum values exceed the recommended range. When serum PTH values are already within target ranges, the JSDT guidelines recommend trimonthly measurement \[[@gfw020C6]\], which is consistent with our finding that measuring PTH more frequently than trimonthly was not associated with higher likelihood of maintaining target ranges. The relationship between increased frequency of PTH monitoring and greater likelihood of achieving the target range was also supported in part by our finding that increased frequency of measurement was associated with greater likelihood of future VDRA use.

Regarding the appropriate frequency of serum calcium/phosphorus measurements, our present results are partially consistent with frequencies found in the guidelines of JSDT. When the serum calcium/phosphorus levels exceed the target ranges, the JSDT guideline recommends more frequent measurements (than biweekly or monthly) \[[@gfw020C6]\]. In the present study, weekly---but not biweekly---calcium/phosphorus measurement was associated with increased likelihood of achieving target ranges, though only for serum calcium. When serum calcium/phosphorus values are already within the target ranges, the JSDT guidelines recommend biweekly or monthly measurement \[[@gfw020C6]\], which is consistent with our finding that measuring calcium/phosphorus more frequently than monthly was not associated with a higher likelihood of maintaining target ranges for both serum calcium and phosphorus.

The relationship between increased frequency of calcium monitoring and greater likelihood of achieving the target range was also supported in part by our findings that increased frequency of calcium/phosphorus measurement was associated with greater likelihood of cinacalcet initiation. Given that cinacalcet has a calcium-lowering effect in addition to its PTH-lowering effect \[[@gfw020C16], [@gfw020C17]\], Japanese dialysis physicians will likely prescribe cinacalcet to SHPT patients on the basis of serum calcium values, as serum calcium is measured more frequently than serum PTH. This notion is further supported by our finding that likelihood of cinacalcet initiation dose dependently increased with increased frequency of serum calcium/phosphorus measurements, but not with increased frequency of serum PTH measurements. In contrast to findings for serum calcium, however, likelihood of achieving the target range for serum phosphorus was not associated with measurement frequency, even when serum phosphorus values exceeded the target range. Although the reason for this discrepancy is unclear, it may be associated with difficulties in serum phosphorus management due to excessive dietary phosphorus intake.

Several strengths to this study should be noted. First, we analyzed the association between monitoring frequency and achievement of target ranges using a large-scale cohort study, with adjustment for important potential confounders that vary over time, such as mineral metabolism markers and therapeutic regimens. Secondly, the unique measurement pattern for serum calcium/phosphorus levels (weekly/biweekly) observed in Japanese settings allowed us to analyze the effectiveness of intensive monitoring patterns on the likelihood of achieving target ranges or prescription change. In contrast, a previous before--after study in the USA was only able to examine the change in likelihood of achieving target ranges of PTH, calcium and phosphorus values after switching from trimonthly to monthly \[[@gfw020C10]\], which is less frequent than the 'intensive monitoring (weekly/biweekly)' pattern adopted in some Japanese facilities, likely because US facilities comply with the KDIGO guideline, whereas Japanese facilities comply with the JSDT guidelines (Table [1](#gfw020-T1){ref-type="table"}).

In addition to the aforementioned strengths, we also feel that the present findings may positively influence the work of dialysis physicians and experts, for several reasons. First, our results provide supporting evidence for experts to draft clinical practice guidelines regarding optimum monitoring frequency. Of note, however, our findings generally support the KDOQI 2003 guidelines versus the KDIGO 2009 guidelines. Secondly, our findings support the notion that dialysis physicians (particularly in Japan) should order routine measurements judiciously. In Japan\'s healthcare system, payments for routine measurements such as calcium, phosphorus and PTH evaluation are reimbursed to facilities up to once a month. As such, refraining from facility-wide 'intensive monitoring' (such as every 1--2 weeks) except for patients who receive active SHPT treatment such as VDRA pulse therapy or cinacalcet may aid in facility management. We hope that the next versions of the KDIGO and JSDT guidelines will harmonize and include statements on reasonable monitoring frequency from evidence-based and economic perspectives.

However, despite the strengths, we feel that several limitations to this study warrant mention. First, we were unable to address potential factors that might improve mineral metabolism, such as frequency of patient--doctor contact and diet instruction by a dietitian to restrict dietary phosphorus. Of note, we did adjust for treatment variables, including VDRA, cinacalcet and phosphate binder administration, which would be prescribed as a result of patient--doctor contact. We therefore believe that any influence of absence of information on patient--doctor contact on our analysis is negligible. Regarding diet instruction, educating patients on eating behavior has been reported to be effective in reducing serum phosphorus levels \[[@gfw020C18]\]. However, given that the effectiveness of diet instruction varies by approach \[[@gfw020C18]\], with no standardized approaches established, and is provided on an individual basis, we were unable to predict in which direction and to what extent the association between monitoring frequency and achievement/maintenance of targeted phosphorus levels might be confounded by diet instruction. Secondly, frequency of measurement was determined on the basis of facility-level policy, which may not be consistently applied to all patients within a facility. To compensate for this issue, we excluded facilities that reported measuring frequencies on an individual basis. Thirdly, precise methods for assays measuring iPTH or whole PTH were not available and thus were unable to be accounted for. As was noted in the DOPPS study \[[@gfw020C3]\], inability to control for differences in assays may lead to increased variability in levels of PTH, which may have biased results toward the null (i.e. toward non-significant associations). Indeed, sensitivity analyses restricted to facilities using iPTH assays yielded similar but slightly stronger associations than those from primary analyses without restriction. Fourth, precise methods for assays measuring serum albumin levels (e.g. bromocresol purple or bromocresol green) were not available \[[@gfw020C19]\]; thus we were unable to assess how much corrected calcium values were affected by serum albumin assays. Fifth, we were unable to examine associations between monitoring frequency with adjustment for phosphate binders because data on dosage were unavailable and were recorded as multinomial categories.

In conclusion, our results suggest that increasing frequency of measurements is helpful when serum marker levels exceed the target range, partially via adjustment in the therapeutic regimen. We found no evidence that frequent measurements are helpful when mineral levels are already within target ranges. Dialysis experts should take these results into account when generating the next version of clinical practice guidelines.

S UPPLEMENTARY DATA {#s5}
===================

[Supplementary data are available online at http://ndt.oxfordjournals.org](#sup1){ref-type="supplementary-material"}.
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[^1]: K.Y. and N.K. are co-first authors.

[^2]: KDOQI, Kidney Disease Outcomes Quality Initiative; JSDT, Japanese Society for Dialysis Therapy; KDIGO, Kidney Disease: Improving Global Outcomes.

[^3]: ^a^Recommended if concomitant therapy for relevant mineral markers is being provided.

[^4]: ^b^Recommended if serum calcium or phosphorus levels deviate from target ranges.

[^5]: ^c^Recommended if concomitant therapy for relevant mineral markers is being provided or if serum levels of relevant mineral markers are abnormal.

[^6]: ^d^Recommended if PTH levels deviate from the target range, if therapies are changed or if active therapy for SHPT is started.

[^7]: SD, standard deviation.

[^8]: ^a^Corrected for albumin concentration using the modified Payne method.

[^9]: ^b^Cinacalcet was not marketed at baseline.

[^10]: ^a^Proportion of sets in which mineral marker levels were in the target range when levels had exceeded the range at previous visit.

[^11]: ^b^AORs and 95% CIs were estimated via generalized estimating equations to account for correlation between intra-individual repeated measurements with adjustment for covariates listed in [Supplementary data, Table S3](#sup1){ref-type="supplementary-material"}.

[^12]: ^c^Proportion of sets in which mineral marker levels were still in the target range when levels had been within the range at previous visit.

[^13]: ^a^Proportion of sets in which cinacalcet was first prescribed.

[^14]: ^b^AORs and 95% CIs were estimated via generalized estimating equations to account for correlation between intra-individual repeated measurements with adjustment for covariates listed in [Supplementary data, Table S3](#sup1){ref-type="supplementary-material"} (age, sex, vintage, primary diseases, comorbidities, use of MBD-related drugs, calcium concentration in dialysate, Kt/V, serum albumin, phosphorus, calcium and PTH).

[^15]: ^a^Proportion of sets in which intravenous VDRA was prescribed at the assessment visit.

[^16]: ^b^AORs and 95% CIs were estimated via generalized estimating equations to account for correlation between intra-individual repeated measurements with adjustment for covariates listed in [Supplementary data, Table S3](#sup1){ref-type="supplementary-material"} (age, sex, vintage, primary diseases, comorbidities, use of MBD-related drugs, calcium concentration in dialysate, Kt/V, serum albumin, phosphorus, calcium and PTH).
